2024-03-28T19:56:22Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/540462022-11-17T02:08:08Zhdl_2115_20044hdl_2115_124Regulation of the Expression and Activity of Glucose and Lactic Acid Metabolism-Related Genes by Protein Kinase C in Skeletal Muscle CellsOtake, Sho1000070431319Kobayashi, MasakiNarumi, KatsuyaSasaki, ShotaroKikutani, YurikaFurugen, AyakoWatanabe, MeguhoTakahashi, Natsuko1000020580640Ogura, Jiro1000080400373Yamaguchi, Hiroaki1000040203062Iseki, Kenopen accessglycolysisprotein kinase Cskeletal muscle499Protein kinase C (PKC) modulators are very attractive therapeutic targets in cancer. Since most cancer cells display increased glycolysis, elucidations of the effects of PKC activation on glycolysis is necessary for the development of effective medicine. In the present study, to clarify the role of PKC in the regulation of glycolysis, we examined the effect of phorbol 12-myristate 13-acetate (PMA), a PKC activator, on the expression and activity of glucose and lactic acid metabolism-related genes in human rhabdomyosarcoma cells (RD cells). In parallel to increases in glucose uptake and mRNA levels of glucose transporters (GLUTs) induced by PMA treatment for 6h, the hexokinase (HK) mRNA level and activity were also significantly increased in RD cells. On the other hand, a significant increase in lactate dehydrogenase (LDH) mRNA level and activity was seen when the cells were incubated with PMA for 24h, but not for 6 or 12h, and was associated with lactic acid production. These effects by PMA treatment were markedly suppressed by Bisindolylmaleimide (BIM), a PKC inhibitor. Furthermore, chetomin, a hypoxia-inducible factor 1 (HIF-1) inhibitor, completely abrogated the increment of LDH mRNA level and activity as well as monocarboxylate transporter (MCT) 4, a lactic acid efflux transporter. In conclusion, we found that HK and LDH activity induced by PKC activation was associated with the glucose uptake and lactic acid level and that LDH and MCT4 are modulated by a common factor, HIF-1.Pharmaceutical soc japan2013-09engjournal articleVoRhttp://hdl.handle.net/2115/54046https://doi.org/10.1248/bpb.b13-00141239956540918-6158Biological & pharmaceutical bulletin36914351439https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/54046/1/WoS_62587_Iseki_Biol_Pharm_Bull.pdfapplication/pdf587.49 KB2013-09